Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
65.54
+5.00 (8.26%)
May 21, 2025, 4:00 PM - Market closed
Arcellx Revenue
Arcellx had revenue of $8.13M in the quarter ending March 31, 2025, a decrease of -79.29%. This brings the company's revenue in the last twelve months to $76.81M, down -41.66% year-over-year. In the year 2024, Arcellx had annual revenue of $107.94M, down -2.16%.
Revenue (ttm)
$76.81M
Revenue Growth
-41.66%
P/S Ratio
46.24
Revenue / Employee
$471,221
Employees
163
Market Cap
3.61B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ACLX News
- 15 hours ago - Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire
- 7 days ago - Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - Business Wire
- 13 days ago - Arcellx Provides First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 22 days ago - Baron Health Care Fund Q1 2025 Top Net Purchases And Sales - Seeking Alpha
- 22 days ago - Baron Health Care Fund Q1 2025 Top Contributors And Detractors - Seeking Alpha
- 2 months ago - Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors - Business Wire
- 2 months ago - Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month - GlobeNewsWire
- 2 months ago - Arcellx Impressive Safety Data Leaves Doubts - Seeking Alpha